Literature DB >> 6542369

Endocrinological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14).

J de Visser, A Coert, H Feenstra, J van der Vies.   

Abstract

A novel steroid, (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14), is described which has concomitant weak estrogenic, progestational and androgenic activities. This hormonal profile was demonstrated using various endocrinological tests and the results were evaluated in terms of well-known reference compounds. It has been well established that combinations of estrogens, androgens and progestagens exert positive or synergistic effects on certain target organs, e.g. the hypothalamic-pituitary axis, and antagonistic or complementary effects on others, e.g. on the endometrium. Org OD 14 with estrogenic, androgenic and progestational activities can therefore be expected to induce complex effects on various target organs. This explains the observed effects of the compound on hypothalamic-pituitary axis, bone-loss, endometrium and sexual behaviour.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6542369

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

1.  Effect of prolonged use of high dose of tibolone on the vagina of ovariectomized rats.

Authors:  Helene Nara Henriques; Ana Carolina Bergmann de Carvalho; Porphirio José Soares Filho; José Augusto Soares Pantaleão; Maria Angélica Guzmán-Silva
Journal:  Int J Exp Pathol       Date:  2011-04-26       Impact factor: 1.925

2.  Effect of tibolone on postmenopausal bone loss.

Authors:  J Rymer; M G Chapman; I Fogelman
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

3.  Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.

Authors:  J M Plumb; J F Guest
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

4.  The in vivo metabolism of tibolone in animal species.

Authors:  C H J Verhoeven; R M E Vos; L P C Delbressine
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

5.  Therapeutic effects of nandrolone decanoate, tibolone, lynestrenol and ethylestrenol on Sjögren's syndrome-like disorder in NZB/W mice.

Authors:  H A Verheul; L P Schot; H W Schuurs
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

6.  Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.

Authors:  Ingrid J M Duijkers; Christine Klipping; Yvette Zimmerman; Nicole Appels; Maud Jost; Catherine Maillard; Marie Mawet; Jean-Michel Foidart; Herjan J T Coelingh Bennink
Journal:  Eur J Contracept Reprod Health Care       Date:  2015       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.